← all works
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- HER2/EGFR in Cancer Research
- Field
- Medicine
- Canadian institutions
- BC Cancer AgencyInstitute of Cancer Research
- Funders
- —
- Keywords
- TrastuzumabMedicineInternal medicineHazard ratioBreast cancerOncologyClinical endpointClinical trialChemotherapyAdjuvantCancerSurgeryConfidence interval
- Has abstract in OpenAlex
- no